Glenmark Pharma receives tentative ANDA nod for Calcipotriene and Betamethasone Dipropionate Foam

Glenmark Pharma receives tentative ANDA nod for Calcipotriene and Betamethasone Dipropionate Foam

by admin- Monday, May 9th, 2022 05:06:17 PM

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted tentative approval by using the United States Food & Drug Administration (USFDA) for Calcipotriene and Betamethasone Dipropionate Foam, zero.0.50.064%, the well-known model of Enstilar 1 Foam, 0.0.5zero.064%, of Leo Pharma AS.

News Updates